» Articles » PMID: 23731608

Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: a Review of the Society of Thoracic Surgeons Database

Overview
Journal Ann Thorac Surg
Publisher Elsevier
Date 2013 Jun 5
PMID 23731608
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Clinical staging of esophageal cancer has improved with positron-emission tomography/computed tomography and endoscopic ultrasound imaging. Despite such progress, small single-center studies have questioned the reliability of clinical staging of T2 N0 esophageal cancer. This study broadly examines the adequacy of clinical staging of T2 N0 disease using The Society of Thoracic Surgeons database.

Methods: We retrospectively studied 810 clinical stage T2 N0 patients from 2002 to 2011, with 58 excluded because of incomplete pathologic staging data. Clinical stage, pathologic stage, and preoperative characteristics were recorded. Logistic regression analysis was used to identify factors associated with upstaging at the time of surgical intervention.

Results: Among 752 clinical stage T2 N0 patients, 270 (35.9%) received induction therapy before the operation. Of 482 patients who went directly to surgical intervention, 132 (27.4%) were confirmed as pathologic T2 N0, 125 (25.9%) were downstaged (ie, T0-1 N0), and 225 (46.7%) were upstaged at the operation (T3-4 N0 or Tany N1-3). Exclusive tumor upstaging (ie, pathologic T3-4 N0) accounted for 41 patients (18.2%), whereas exclusive nodal upstaging (ie, pathological T1-2 N1-3) accounted for 100 (44.5%). Combined tumor and nodal upstaging (ie, pathological T3-4 N1-3) accounted for 84 patients (37.3%). Among patients who received induction therapy, 103 (38.1%) were upstaged vs 225 (46.7%) without induction therapy (p = 0.026). Comparing the induction therapy group and the primary surgical group, postoperative 30-day mortality (3.7% vs 3.7%, p > 0.99) and morbidity (46.3% vs 45%, p = 0.76) were similar.

Conclusions: Despite advances in staging techniques, clinical staging of T2 N0 esophageal cancer remains unreliable. Recognizing T2 N0 as a threshold for induction therapy in esophageal cancer, many surgeons have opted to treat T2 N0 disease with induction therapy, even though one-quarter of these patients will be pathologic T1 N0. Although this study demonstrated similar perioperative morbidity and mortality with and without induction therapy, further study is needed to examine the effect of upstaging on long-term survival.

Citing Articles

Clinical staging to differentiate T2 and T3 esophageal squamous cell carcinomas-essential details or just noise?.

Groth S J Thorac Dis. 2024; 16(11):7230-7232.

PMID: 39678881 PMC: 11635233. DOI: 10.21037/jtd-24-491.


Radiomics in Oesogastric Cancer: Staging and Prediction of Preoperative Treatment Response: A Narrative Review and the Results of Personal Experience.

Garbarino G, Polici M, Caruso D, Laghi A, Mercantini P, Pilozzi E Cancers (Basel). 2024; 16(15).

PMID: 39123392 PMC: 11311587. DOI: 10.3390/cancers16152664.


Comparison of long-term survival of neoadjuvant therapy plus surgery versus upfront surgery and the role of adjuvant therapy for T1b-2N0-1 esophageal cancer: a population study of the SEER database and Chinese cohort.

Xia L, Shi W, Cai Y, Liao Z, Huang Z, Qiu H Int J Surg. 2024; 111(1):70-79.

PMID: 38920327 PMC: 11745756. DOI: 10.1097/JS9.0000000000001886.


Collaborative multidisciplinary management and expertise of cT2-3 locally advanced operable esophageal squamous cell carcinoma: a report of two cases.

Leng X, Kurita D, Zhu Y, Abe S, Zhang R, Guo X J Thorac Dis. 2023; 15(11):6362-6372.

PMID: 38090303 PMC: 10713291. DOI: 10.21037/jtd-23-1277.


Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study.

Park S, Lee Y, Lee J, Min Y, Kim H, Choi J Cancer Res Treat. 2023; 56(2):567-579.

PMID: 37846467 PMC: 11016664. DOI: 10.4143/crt.2023.897.


References
1.
Graham A, Shrive F, Ghali W, Manns B, Grondin S, Finley R . Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg. 2007; 83(4):1257-64. DOI: 10.1016/j.athoracsur.2006.11.061. View

2.
Rice T, Blackstone E, Adelstein D, Zuccaro Jr G, Vargo J, Goldblum J . Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma. J Thorac Cardiovasc Surg. 2003; 125(5):1091-102. DOI: 10.1067/mtc.2003.404. View

3.
Urschel J, Vasan H, Blewett C . A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2002; 183(3):274-9. DOI: 10.1016/s0002-9610(02)00795-x. View

4.
Rice T, Blackstone E, Rusch V . 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010; 17(7):1721-4. DOI: 10.1245/s10434-010-1024-1. View

5.
Malthaner R, Wong R, Spithoff K . Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol). 2010; 22(4):250-6. DOI: 10.1016/j.clon.2010.02.005. View